Medivation, Inc. (NASDAQ: MDVN) will be hosting a presentation at JP Morgan's 28th Annual Healthcare Conference. The President and CEO of Medivation, David Hung, M.D., will host the presentation, providing an overview of the company and its clinical development programs for dimebon in use for Alzheimer's and Huntington diseases and MDV3100 for use in prostate cancer. Dr. Hung is scheduled to give his presentation on January 11, 2010 at 3:30pm (PST). The presentation will be made available both live and for replay over the Investor Relations section of the company's website.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
